TITLE

Questionable recommendations for cholinesterase inhibitor use in AD

PUB. DATE
August 2005
SOURCE
PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses research being done on the use of cholinesterase inhibitors for patients with Alzheimer's disease. Reference to a study by Hanna Kaduszkiewicz and colleagues, published in the August 2005 issue of the "British Medical Journal"; Methodology of the study.
ACCESSION #
18148646

 

Related Articles

  • Do patients at high risk of Alzheimer's disease benefit from early treatment? Holt, Jim; Stiltner, Lynetta; Wallace, Rick // Journal of Family Practice;Jun2009, Vol. 58 Issue 6, p320 

    The article reports on the study that evaluates the benefits of early treatment in patients with high risk of Alzheimer's disease. It recognizes that fair to good evidence supports a benefit from treatment of early-stage Alzheimer's disease. It suggests that routine screening for dementia in...

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...

  • Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine. Wei-Wei Zhang; Zu-Peng Xu; Yong-Yao Cui; Hao Wang; Ming-Ke Song; Juan Li; Bi-Yun Shao; Zheng Xia; Hong-Zhuan Chen // Journal of Neural Transmission;Dec2009, Vol. 116 Issue 12, p1643 

    Rivastigmine is a potent acetyl- and butyrylcholinesterase inhibitor widely used for cognitive improvement in Alzheimer’s disease (AD) therapy. However, dose-limiting adverse effects restrict its tolerability and clinical outcomes. This study explored new combined therapy, in which...

  • Contemporary drug treatment. Hines, Silvia E. // Patient Care;2/15/2001, Vol. 35 Issue 3, p54 

    Presents information on cholinesterase inhibitors that can delay the progression of dementia associated with Alzheimer's disease (AD). Trials of cholinesterase inhibitor drugs used; Side effects of the drugs; Prescription processes; Antioxidants and hormones used for AD therapy. INSETS:...

  • Review: cholinesterase inhibitors may be effective in Alzheimer's disease. Kaduszkiewicz, H.; Zimmernann, T.; Beck-Bornholdt, H. P. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p23 

    The article reports on a study which reviews various research to determine whether treatment with cholinesterase inhibitors can enhance clinical outcomes in patients with Alzheimer's disease. The research showed that cholinesterase inhibitors were indeed effective, but these randomized...

  • New Acetylcholinesterase Inhibitors for Alzheimer's Disease. Mehta, Mona; Adem, Abdu; Sabbagh, Marwan // International Journal of Alzheimer's Disease;2012, p1 

    Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE...

  • Risk of Antipsychotic Drug Use in Patients with Alzheimer's Disease Treated with Rivastigmine. Suh, Dong-Churl; Arcona, Stephen; Thomas, Simu K.; Powers, Christopher; Rabinowicz, Adrian L.; Shin, Hyunchul; Mirski, Dario // Drugs & Aging;2004, Vol. 21 Issue 6, p395 

    Background and Objective: Cholinesterase inhibitors may offer some improvement in the behavioural symptoms of Alzheimer' s disease. The dual inhibitory mechanism of action of rivastigmine (inhibition of acetylcholinesterase and butyrylcholinesterase) may improve behavioural symptoms and may...

  • EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. Kogan, E. A.; Korczyn, A. D.; Virchovsky, R. G.; Klimovizky, S. Sh.; Treves, T. A.; Neufeld, M. Y. // Journal of Neural Transmission;Oct2001, Vol. 108 Issue 10, p1167 

    Summary. In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during...

  • Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. Rainer, M.; Mucke, H. A. M.; Krüger-Rainer, C.; Kraxberger, E.; Haushofer, M.; Jellinger, K. A. // Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1327 

    Summary. In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics